Market Momentum: DermTech Inc (DMTK) Registers a -3.14 Decrease, Closing at 0.11

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

DermTech Inc (NASDAQ: DMTK) closed the day trading at $0.11 down -3.14% from the previous closing price of $0.12. In other words, the price has decreased by -$3.14 from its previous closing price. On the day, 41.06 million shares were traded. DMTK stock price reached its highest trading level at $0.1504 during the session, while it also had its lowest trading level at $0.1131.


For a better understanding of DMTK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.46 and its Current Ratio is at 3.53. In the meantime, Its Debt-to-Equity ratio is 1.34 whereas as Long-Term Debt/Eq ratio is at 1.26.

On June 14, 2022, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $38 to $19.

On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $26.Stephens initiated its Overweight rating on January 07, 2022, with a $26 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’23 when Sun Kevin M sold 447 shares for $1.45 per share. The transaction valued at 648 led to the insider holds 277,499 shares of the business.

Ibarra Claudia sold 331 shares of DMTK for $480 on Dec 11 ’23. The Chief Operating Officer now owns 193,547 shares after completing the transaction at $1.45 per share. On Dec 08 ’23, another insider, Ibarra Claudia, who serves as the Chief Operating Officer of the company, sold 2,607 shares for $1.41 each. As a result, the insider received 3,676 and left with 193,878 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DMTK now has a Market Capitalization of 3992774 and an Enterprise Value of 18682774. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.25 while its Price-to-Book (P/B) ratio in mrq is 0.10. Its current Enterprise Value per Revenue stands at 1.193 whereas that against EBITDA is -0.221.

Stock Price History:

The Beta on a monthly basis for DMTK is 2.43, which has changed by -0.94887894 over the last 52 weeks, in comparison to a change of 0.26238096 over the same period for the S&P500. Over the past 52 weeks, DMTK has reached a high of $3.90, while it has fallen to a 52-week low of $0.11. The 50-Day Moving Average of the stock is -76.36%, while the 200-Day Moving Average is calculated to be -89.78%.

Shares Statistics:

Over the past 3-months, DMTK traded about 782.10K shares per day on average, while over the past 10 days, DMTK traded about 5810670 shares per day. A total of 34.52M shares are outstanding, with a floating share count of 31.79M. Insiders hold about 9.08% of the company’s shares, while institutions hold 13.07% stake in the company. Shares short for DMTK as of 1715731200 were 2849018 with a Short Ratio of 4.30, compared to 1713139200 on 3083222. Therefore, it implies a Short% of Shares Outstanding of 2849018 and a Short% of Float of 8.3100006.

Earnings Estimates

Investors are keenly observing as 2.0 analysts analyze and rate the current performance of DermTech Inc (DMTK) in the stock market.On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.42 and a low estimate of -$0.52, while EPS last year was -$0.99. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.44 and low estimates of -$0.52.

Analysts are recommending an EPS of between -$1.87 and -$2.12 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$2.08, with 1.0 analysts recommending between -$2.08 and -$2.08.

Revenue Estimates

2 analysts predict $4.27M in revenue for the current quarter. It ranges from a high estimate of $4.6M to a low estimate of $3.95M. As of the current estimate, DermTech Inc’s year-ago sales were $3.69MFor the next quarter, 2 analysts are estimating revenue of $4.69M. There is a high estimate of $5.2M for the next quarter, whereas the lowest estimate is $4.19M.

A total of 2 analysts have provided revenue estimates for DMTK’s current fiscal year. The highest revenue estimate was $19.8M, while the lowest revenue estimate was $16.2M, resulting in an average revenue estimate of $18M. In the same quarter a year ago, actual revenue was $15.3MBased on 1 analysts’ estimates, the company’s revenue will be $17.4M in the next fiscal year. The high estimate is $17.4M and the low estimate is $17.4M.

Most Popular